Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MNPR
MONOPAR THERAPEUTICS INC.
NASDAQ
$111.89
▼ DOWN 1.80% (-2.05)

KEY STATISTICS

Market Cap$749.56 M
52w High$124.82
52w Low$32.77
Dividend Yield—
Frequency—
P/E-51.56
Volume221.54K
Shares Out.6.70M

COMPANY

LEADERSHIP

Chandler D. Robinson
CHIEF EXECUTIVE
Chandler D. Robinson

COMPENSATION 2026

Salary$700,000
Stock Awards$6,263,958
Incentive Plan Pay$420,000
All Other Comp.$0
Total$10,637,821

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 19, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
22

PRICE TARGET

Target High$133.00
Target Low$105.00
Target Median$125.00
Target Consensus$123.57

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2024-08-13Reverse1:5

PRICE

$111.89 ▼ DOWN 1.80% (−$2.05)
OVERLAYS
$110$111$1139:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM111.89

About Monopar Therapeutics Inc.

https://www.monopartx.com ↗

Monopar Therapeutics Inc. is a clinical-stage biopharma developing cancer treatments, including Validive for oral mucositis and novel agents like Camsirubicin and MNPR-101, with collaborations across cancer and COVID-19 therapeutics.

INDUSTRY

Biotechnology

A PRODUCT MONOPAR THERAPEUTICS INC. IS KNOWN FOR

ALXN1840
ALXN1840

Monopar's late-stage, once-daily oral investigational medicine for Wilson Disease, a rare genetic disorder causing copper poisoning, has completed Phase 3 trials and is preparing for a potential New Drug Application.

COMPETITORS

COMPETITOR
ATAI COMPARE
COLL COMPARE
OCS COMPARE
TRVI COMPARE
UPB COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
61
LISTED HERE
11
RANKED BY POSITION SIZE
VTS.AX
0.00% · 159.8K
IWM
0.02% · 117.2K
ZPRR.DE
0.02% · 9.8K
BBC
1.14% · 5.2K
AVSC
0.02% · 4.8K
XRSU.L
0.02% · 4.1K
GSSC
0.03% · 3.3K
RSSL
0.02% · 2.2K
URTY
0.01% · 183
RESM
0.02% · 9
RTYS.L
0.02% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
75.97%
HOLDERS
95
TOP 12 OF 95 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
1.3M sh · $72.06M
Ra Capital Management, L.P.
667.2K sh · $36.56M
Adage Capital Partners Gp, L.L.C.
659.2K sh · $53.84M
Saturn V Capital Management LLC
345.6K sh · $18.94M
Deerfield Management Company, L.P. (Series C)
323.7K sh · $17.74M
Blackrock, Inc.
316.6K sh · $17.34M
Vanguard Group Inc
293.8K sh · $19.19M
Siren, L.L.C.
270.1K sh · $14.8M
Adar1 Capital Management, LLC
264.3K sh · $14.48M
Wellington Management Group Llp
231.5K sh · $18.9M
Polar Capital Holdings Plc
226.5K sh · $12.41M
Sio Capital Management, LLC
173.5K sh · $9.51M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity5
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Tsuchimoto Kim R
Purchase · 2.0K shares
2026-08-26
★
DIRECTOR
Tsuchimoto Kim R
Purchase · 2.1K shares
2026-08-26
★
DIRECTOR
Tsuchimoto Kim R
Purchase · 2.0K shares
2026-08-26
★
DIRECTOR
Tsuchimoto Kim R
Sale · 485 shares
2026-08-26

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
OUTPERFORM 2
NEUTRAL 1
8 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Cantor Fitzgerald NEUTRAL BTIG BUY HC Wainwright & Co. BUY Chardan Capital BUY Raymond James OUTPERFORM Oppenheimer OUTPERFORM Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
OMER$18.61COMPARE
LXRX$2.29COMPARE
FDMT$14.67COMPARE
CMPX$2.40COMPARE
FULC$3.85COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
AKBA$0.88COMPARE